Letters to the Editor
1 Department of Neurology, Meyer 2-147, Johns Hopkins Hospital, Baltimore, MD 21205
We read with interest the report of Drs Hunt and Pellock on screening a population of institutionalized patients for carnitine deficiency. There did not appear to be any substantial correlation between the carnitine levels and the patient's function, handicap, or the ingestion of anticonvulsants. This population could be useful for a blinded test of the reported beneficial effects of carnitine administration.
The letter from Sigma-Tau Pharmaceuticals, manufacturers of Carnitor, is, I believe, an intentionally misleading and disingenuous extension of their advertising campaign of which my quote is the opening sentence.
This article has been cited by other articles:
![]() |
S. Kurul, E. Dirik, and A. IIscan Serum Carnitine Levels During Oxcarbazepine and Carbamazepine Monotherapies in Children With Epilepsy J Child Neurol, August 1, 2003; 18(8): 552 - 554. [Abstract] [PDF] |
||||
![]() |
M. J. Romano and A. Dinh A 1000-Fold Overdose of Clonidine Caused by a Compounding Error in a 5-Year-Old Child With Attention-Deficit/Hyperactivity Disorder Pediatrics, August 1, 2001; 108(2): 471 - 472. [Abstract] [Full Text] |
||||






